In several KRAS G12C NSCLC cell lines, primarily those with TP53 and/or LKB1 mutations, newly synthesized KRAS is detected by western blotting within 72 h after treatment with a G12C inhibitor (ARS1620) with downstream ERK phosphorylation60. Here, TP53 is linked to non-small cell lung carcinoma.